Analysis on the current situation of China's antiarrhythmic drug industry in 2021: domestic R & D is further [figure]

One 、 Number of cardiovascular patients

At present, cardiovascular disease has become one of the most serious diseases threatening human beings , The market scale of cardiovascular drugs in China is also growing with the increase of patients , But growth slowed . In the medication of cardiovascular diseases in China , The main target drug is dirty 、 Renin and lipid mediating drugs .2020 The number of cardiovascular patients in China was about 3.4 Hundreds of millions of people , Year-on-year growth 3.03%.

2016-2020 The number and growth rate of cardiovascular patients in China in

source ： Zhiyan consultation and arrangement

One 、 Antiarrhythmic drugs

Antiarrhythmic drugs , It can prevent and cure tachycardia 、 Drugs for bradycardia or arrhythmia . But generally refers to the prevention and treatment of tachycardia and some arrhythmia drugs . According to the epidemiological statistics of atrial fibrillation , The incidence rate of atrial fibrillation in China increases with age ,70 Before the age of , The incidence rate of male is higher than that of female ,70 The incidence rate of female is higher than that of male , The number of patients with atrial fibrillation in China is nearly ten million , Due to the low awareness rate , First diagnosis of atrial fibrillation only 0.37%. among 2020 The annual sales volume of amiodarone is about 2021.82 Thousands of dollars .

2020 Sales of major antiarrhythmic drugs in China in

source ： Zhiyan consultation and arrangement

Propafenone , It is a broad-spectrum high-performance membrane inhibitory antiarrhythmic drug , It has membrane stability and competitiveness β Receptor blockade . Can reduce myocardial excitability , Prolonging action potential duration and effective refractory period , Prolonged conduction .2021 The sales revenue of propafenone in China was 144.23 Thousands of dollars , Year-on-year decline in 57.86%.

2018-2021 Sales revenue and growth rate of propafenone in China in

source ： Zhiyan consultation and arrangement

Two 、 Antiarrhythmic drug enterprises

At present, the stone Pharmaceutical Group is engaged in nervous system diseases 、 Anti tumor 、 There is a strong product portfolio in the treatment fields of anti infection and cardiovascular diseases , among 「 Enbip 」、「 Domaine 」、「 PEG-rhG-CSF 」、「 Kelly 」、「 Xuanning 」 And other innovative products that sell well in China . API products mainly include vitamins C、 Antibiotics and caffeine series .
Listing of dronedarone hydrochloride tablets of stone Pharmaceutical Group , It fills the gap that there is no such drug in China , It is of great significance to improve the accessibility of drugs .

2016-2021 Total operating income and gross profit margin of Shijiazhuang Pharmaceutical Group in

source ： Annual report of the company 、 Zhiyan consultation and arrangement